Matsumoto Shinichi S, Koizumi Hidetaka, Shimazu Hideki, Goto Satoshi
Department of Neurology (SSM), Osaka Neurological Institute; Department of Neurology (HK), Kyoto Prefectural Rehabilitation Hospital for the Disabled, Nakaashihara; Department of Pharmacology (HS), School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Hyogo; Center for Drug Discovery and Development Sciences (SG), Research Organization of Science and Technology, Ritsumeikan University, Kyoto; and Department of Clinical Neuroscience (SG), Institute of Biomedical Sciences, Tokushima University, Japan.
Neurol Clin Pract. 2024 Apr;14(2):e200254. doi: 10.1212/CPJ.0000000000200254. Epub 2024 Jan 5.
Imbalanced activities between dopamine D and D signals in striatal striosome-matrix system have been proposed as a cause of dystonia symptoms. The aim of this study was to assess the therapeutic effects of dual dopaminergic modulation (DDM) with l-DOPA and chlorpromazine (CPZ) in patients with idiopathic cervical dystonia (CD).
We enrolled 21 patients with CD who responded poorly to botulinum toxin treatment. The severities of CD motor symptoms and CD-associated pain were determined using the Toronto Western Spasmodic Torticollis Rating Scale and the visual analog scale, respectively.
In patients with CD (n = 7), oral administration of l-DOPA combined with CPZ significantly attenuated both CD motor symptoms and CD-associated pain in a dose-related manner. By contrast, there was no improvement of CD symptoms in patients (n = 7) who ingested l-DOPA alone nor in those (n = 7) who ingested CPZ alone.
DDM with l-DOPA and CPZ may be an effective tool to treat dystonia symptoms in patients with botulinum toxin-resistant idiopathic CD. Our results may also indicate that CD dystonia symptoms could be attenuated through DDM inducing an increase in striosomal D-signaling.
This study provides Class III evidence that treatment of botulinum toxin-resistant idiopathic cervical dystonia with l-DOPA and chlorpromazine is superior to either one alone.
纹状体纹状小体 - 基质系统中多巴胺D和D信号之间的活动失衡被认为是肌张力障碍症状的一个原因。本研究的目的是评估左旋多巴和氯丙嗪(CPZ)双重多巴胺能调节(DDM)对特发性颈部肌张力障碍(CD)患者的治疗效果。
我们纳入了21例对肉毒毒素治疗反应不佳的CD患者。分别使用多伦多西部痉挛性斜颈评定量表和视觉模拟量表来确定CD运动症状的严重程度和与CD相关的疼痛程度。
在CD患者(n = 7)中,口服左旋多巴联合CPZ以剂量相关的方式显著减轻了CD运动症状和与CD相关的疼痛。相比之下,单独服用左旋多巴的患者(n = 7)和单独服用CPZ的患者(n = 7)的CD症状均无改善。
左旋多巴和CPZ的DDM可能是治疗对肉毒毒素耐药的特发性CD患者肌张力障碍症状的有效工具。我们的结果还可能表明,CD肌张力障碍症状可通过DDM诱导纹状小体D信号增加而得到减轻。
本研究提供了III类证据,即左旋多巴和氯丙嗪联合治疗对肉毒毒素耐药的特发性颈部肌张力障碍优于单独使用其中任何一种药物。